Novartis Replaces Japan Unit Head Ninomiya Amid Drug Test Probe

Novartis AG (NOVN) named Dirk Kosche as the head of its Japan business today, replacing Yoshiyasu Ninomiya after investigations showed that the unit involved itself in drug studies that were supposed to be independent of the company.

Novartis needs to rebuild a company in Japan that meets “legal obligations and executes operations ethically” under new management, the Basel, Switzerland-based drugmaker’s Japanese unit said in a statement today.

An investigation by a third-party commission appointed by the company disclosed yesterday that Novartis employees destroyed evidence and may have obtained patients’ personal information during a doctor-led leukemia study. Novartis has faced a string of other problems in Japan, including improper involvement in independent studies on hypertension drug Diovan and cancer treatment Tasigna.

Novartis also said today that it appointed Francis Bouchard to be head of the oncology unit in Japan and Michael Ferris to be head of a holding company in the country. The company is having activities since 2011 reviewed by a third party to search for similar problems and will temporarily suspend supporting independent studies, it said. The review will be completed by summer this year and the company will report the results, it said.

An independent trial which found that Diovan, Novartis’ second-best selling medicine with $3.5 billion in sales in 2013, cut stroke risks in Japanese people, was retracted by the European Heart Journal February last year because “critical problems existed with some of the data reported” in the paper. The data could have been manipulated, according to a report by the university which led the study in July.

The Lancet journal retracted another Japan study on Diovan in September saying “we no longer have confidence in the published results.”

Failed to Disclose

Novartis Japan said in July it failed to disclose the ties of its employees in five such Diovan studies conducted between 2001 and 2004 in Japan. The scope of Novartis’s probe into the research, and whether it was falsified is limited because Novartis doesn’t have access to raw data of the studies, Ninomiya said at that time.

Japan’s health ministry filed a complaint with Tokyo prosecutors against Novartis in January, seeking a criminal investigation of the company for possibly breaching advertising rules with Diovan by exaggerating the medicine’s effectiveness in marketing materials.

Novartis Japan in October said it would set up an outside committee to advise on governance, tighten the process of funding trials and hold seminars internally for prevention. In January, Novartis Japan said its sales staff were involved in a doctor-led study using leukemia drug Tasigna and that it had hired a third party for investigation.

Such actions are “unacceptable and against the ethical standard set by Novartis” and the company will take measures against those employees, it said.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at

To contact the editors responsible for this story: Anjali Cordeiro at Phil Serafino

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.